ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, A
Right arrow Articles by Geddes, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, A
Right arrow Articles by Geddes, D.
Eur Respir J 1993; 6: 1243-1248
Copyright © ERS Journals Ltd 1993

Clinical Trial

No added benefit from nebulized amiloride in patients with cystic fibrosis

A Graham, A Hasani, EW Alton, GP Martin, C Marriott, ME Hodson, SW Clarke, and DM Geddes

In cystic fibrosis (CF) airway epithelial sodium absorption is increased 2-3 fold. Since sodium absorption is inhibited by the sodium channel blocker amiloride, our aim was to assess its therapeutic benefit in cystic fibrosis. A randomized, double-blind, placebo-controlled, cross-over trial of nebulized amiloride was performed in 23 patients with cystic fibrosis. Amiloride or placebo was administered four times daily for two six month periods. Existing treatment was continued, and any infective exacerbations treated in the usual way. Fourteen patients completed the study. No significant changes occurred in forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate during either treatment period. The frequency of infective exacerbations was also not different in either treatment period. We were thus unable to confirm the benefit shown in the only other clinical trial of nebulized amiloride in cystic fibrosis and conclude that, in the presence of established treatment for cystic fibrosis lung disease, nebulized amiloride offers no additional clinical benefit.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
Z. Zhou, D. Treis, S. C. Schubert, M. Harm, J. Schatterny, S. Hirtz, J. Duerr, R. C. Boucher, and M. A. Mall
Preventive but Not Late Amiloride Therapy Reduces Morbidity and Mortality of Lung Disease in {beta}ENaC-overexpressing Mice
Am. J. Respir. Crit. Care Med., December 15, 2008; 178(12): 1245 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Hirsh, J. Zhang, A. Zamurs, J. Fleegle, W. R. Thelin, R. A. Caldwell, J. R. Sabater, W. M. Abraham, M. Donowitz, B. Cha, et al.
Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 77 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. D. Carattino, C. J. Passero, C. A. Steren, A. B. Maarouf, J. M. Pilewski, M. M. Myerburg, R. P. Hughey, and T. R. Kleyman
Defining an inhibitory domain in the {alpha}-subunit of the epithelial sodium channel
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F47 - F52.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. H. Donaldson and R. C. Boucher
Sodium Channels and Cystic Fibrosis
Chest, November 1, 2007; 132(5): 1631 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. G. Middleton, T. J. Kidd, and B. Williams
Combination aerosol therapy to treat Burkholderia cepacia complex
Eur. Respir. J., August 1, 2005; 26(2): 305 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Hirsh, J. R. Sabater, A. Zamurs, R. T. Smith, A. M. Paradiso, S. Hopkins, W. M. Abraham, and R. C. Boucher
Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 929 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. J. Bridges, B. B. Newton, J. M. Pilewski, D. C. Devor, C. T. Poll, and R. L. Hall
Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437
Am J Physiol Lung Cell Mol Physiol, July 1, 2001; 281(1): L16 - L23.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H.C. Rodgers and A.J. Knox
Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Eur. Respir. J., June 1, 2001; 17(6): 1314 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. C. Devor, R. J. Bridges, and J. M. Pilewski
Pharmacological modulation of ion transport across wild-type and Delta F508 CFTR-expressing human bronchial epithelia
Am J Physiol Cell Physiol, August 1, 2000; 279(2): C461 - C479.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. HOFMANN, M. J. STUTTS, A. ZIERSCH, C. RUCKES, W. M. WEBER, M. R. KNOWLES, H. LINDEMANN, and R. C. BOUCHER
Effects of Topically Delivered Benzamil and Amiloride on Nasal Potential Difference in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1844 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. C. Stern
The Diagnosis of Cystic Fibrosis
N. Engl. J. Med., February 13, 1997; 336(7): 487 - 491.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the European Respiratory Society.